Sutro Biopharma, Inc. (STRO) — SEC Filings
Sutro Biopharma, Inc. (STRO) — 41 SEC filings. Latest: EFFECT (Apr 2, 2026). Includes 14 8-K, 11 SC 13G/A, 6 10-Q.
View Sutro Biopharma, Inc. on SEC EDGAR
Overview
Sutro Biopharma, Inc. (STRO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 23, 2026: Sutro Biopharma, Inc. (STRO) is a clinical-stage oncology company that reported a strategic shift in 2025, deprioritizing luveltamab tazevibulin (STRO-002) development after a strategic review in March 2025. The company initiated a Phase 1 trial for its highest priority wholly-owned product candidat
Sentiment Summary
Across 41 filings, the sentiment breakdown is: 2 bullish, 3 bearish, 34 neutral, 2 mixed. The dominant filing sentiment for Sutro Biopharma, Inc. is neutral.
Filing Type Overview
Sutro Biopharma, Inc. (STRO) has filed 1 EFFECT, 1 424B3, 3 10-K, 14 8-K, 6 10-Q, 2 DEF 14A, 11 SC 13G/A, 1 DEFA14A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (41)
Risk Profile
Risk Assessment: Of STRO's 24 recent filings, 4 were flagged as high-risk, 12 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | N/A |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | N/A |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. William D. Young
- Ms. Jennifer L. Jones
- Mr. David E. R. Gray
- Dr. William Newell
- Ms. Jennifer L. Williams
- Mr. William H. R. Newell
- Dr. Pamela L. Wagner
Industry Context
Sutro Biopharma operates within the highly competitive and rapidly advancing field of oncology drug development, with a specific focus on Antibody Drug Conjugates (ADCs). The ADC market is characterized by significant innovation, with companies leveraging advanced platform technologies to create targeted therapies. Key trends include the development of novel payloads, improved conjugation chemistries for homogeneity, and the exploration of new modalities like immunostimulatory ADCs (iADCs) and dual-payload ADCs (dpADCs).
Top Tags
Biotechnology (4) · biopharma (4) · institutional-ownership (4) · Antibody-Drug Conjugates (3) · Clinical Trials (3) · corporate-governance (3) · 10-Q (3) · collaboration (3) · biotech (3) · financials (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| aggregate payments from collaborations | $1.016 billion | received through December 31, 2025, demonstrating significant partnership revenue |
| investments in Sutro stock | $79 million | included in collaboration payments, indicating partner confidence |
| fiscal year ended | 2025 | reporting period for this 10-K filing |
| IND clearance for STRO-004 | October 2025 | key regulatory milestone for lead product candidate |
| Phase 1 trial initiation for STRO-004 | November 2025 | start of clinical development for lead product candidate |
| expected initial data for STRO-004 | mid-2026 | critical upcoming catalyst for the company |
| strategic review and deprioritization of luvelta (STRO-002) | March 2025 | significant pipeline shift |
| shares outstanding | 16,567,238 | as of March 16, 2026 |
| aggregate market value of non-affiliate common equity | $60.0 million | as of June 30, 2025, based on $7.10 closing price |
| Accumulated Deficit | $931.2 million | As of September 30, 2025, indicating significant historical losses. |
| Net Loss (Nine Months) | $144.324 million | For the nine months ended September 30, 2025, an improvement from $155.018 million in 2024. |
| Revenue (Nine Months) | $90.837 million | For the nine months ended September 30, 2025, a substantial increase from $47.234 million in 2024. |
| Cash and Cash Equivalents | $65.927 million | As of September 30, 2025, a significant decrease from $190.304 million at December 31, 2024. |
| Workforce Reduction | Two-thirds | Combined impact of March and September 2025 Restructuring Plans. |
| Common Stock Outstanding | 85,135,290 | As of October 31, 2025. |
Forward-Looking Statements
- {"claim":"Rubric Capital Management LP will maintain its significant stake in Sutro Biopharma, Inc. throughout 2024.","entity":"Rubric Capital Management LP","targetDate":"2024-12-31","confidence":"medium"}
- {"claim":"Sutro Biopharma, Inc.'s stock price will experience increased stability due to continued institutional ownership.","entity":"Sutro Biopharma, Inc.","targetDate":"2024-06-30","confidence":"medium"}
- {"claim":"Sutro Biopharma will release more detailed information regarding the 'Other Events' within the next few days.","entity":"SUTRO BIOPHARMA, INC.","targetDate":"2024-02-16","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Sutro Biopharma, Inc. (STRO)?
Sutro Biopharma, Inc. has 41 recent SEC filings from Jan 2024 to Apr 2026, including 14 8-K, 11 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of STRO filings?
Across 41 filings, the sentiment breakdown is: 2 bullish, 3 bearish, 34 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Sutro Biopharma, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Sutro Biopharma, Inc. (STRO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Sutro Biopharma, Inc.?
Key financial highlights from Sutro Biopharma, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for STRO?
The investment thesis for STRO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Sutro Biopharma, Inc.?
Key executives identified across Sutro Biopharma, Inc.'s filings include Dr. William D. Young, Ms. Jennifer L. Jones, Mr. David E. R. Gray, Dr. William Newell, Ms. Jennifer L. Williams and 2 others.
What are the main risk factors for Sutro Biopharma, Inc. stock?
Of STRO's 24 assessed filings, 4 were flagged high-risk, 12 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Sutro Biopharma, Inc.?
Recent forward-looking statements from Sutro Biopharma, Inc. include guidance on {"claim":"Rubric Capital Management LP will maintain its significant stake in Sutro Biopharma, Inc. throughout 2024.","e and 2 other predictions.